Morphine and remifentanil-induced cardioprotection: Its experimental and clinical outcomes

Korean Journal of Anesthesiology

Volumn 61, Issue 5, 2011, Pages 358-366

  Kim, Jin Mo ^a   Jang, Young Ho ^b   Kim, Jun ^b  

^a Keimyung University   (South Korea)

^b Pusan National University Yangsan Hospital   (South Korea)

Author keywords

Ischemic postconditioning; Ischemic preconditioning; Morphine; Myocardial ischemia; Myocardial reperfusion; Remifentanil

Indexed keywords

ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATASE (POTASSIUM); BW 373 U 86; CARDIAC AGENT; DYNORPHIN; ENDORPHIN; ENKEPHALIN; GLYCOGEN SYNTHASE KINASE 3BETA; KAPPA OPIATE RECEPTOR; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MORPHINE; NALOXONE; OPIATE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; REMIFENTANIL; UNCLASSIFIED DRUG;

HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; NONHUMAN; OPIOID INDUCED CARDIOPROTECTION; REPERFUSION INJURY; REVIEW; TREATMENT OUTCOME;

EID: 82955223333     PISSN: 20056419     EISSN: 20057563     Source Type: Journal    
DOI: 10.4097/kjae.2011.61.5.358     Document Type: Review

References (76)

1. Yellon DM, Downey JM. Preconditioning myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 1113-51.
2. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994; 266: H1145-52.
3. Das DK, Maulik N, Sato M, Ray PS. Reactive oxygen species function as second messenger during ischemic preconditioning of heart. Mol Cell Biochem 1999; 196: 59-67.
4. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005; 15: 69-75.
5. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase-3β during preconditioning through a phosphatidylinositol- 3-kinase-dependent pathway is cardioprotective. Cir Res 2002; 90: 377-9.
6. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002; 55: 534-43.
7. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006; 70: 240-53.
8. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 2003; 100: 4802-6.
9. Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S, et al. Phosphatidylinositol 3-kinase gamma is a crucial mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res 2008; 103: 643-53.
10. Yoshida H, Kusama Y, Kodani E, Yasutake M, Takano H, Atarashi H, et al. Pharmacological preconditioning with bradykinin affords myocardial protection through NO-dependent mechanisms. Int Heart J 2005; 46: 877-87.
11. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, et al. Atorvastatininduced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 2006; 290: H1960-8.
12. Huhn R, Heinen A, Weber NC, Schlack W, Preckel B, Hollmann MW. Ischaemic and morphine-induced post-conditioning: impact of mK(Ca) channels. Br J Anaesth 2010; 105: 589-95.
13. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
14. Schultz JE, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995; 268: H2157-61.
15. Chien GL, Van Winkle DM. Naloxone blockade of myocardial ischemic preconditioning is stereoselective. J Mol Cell Cardiol 1996; 28: 1895-900.
16. Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart. J Mol Cell Cardiol 1997; 29: 1355-62.
17. Zatta AJ, Kin H, Yoshishige D, Jiang R, Wang N, Reeves JG, et al. Evidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation. Am J Physiol Heart Circ Physiol 2008; 294: H1444-51.
18. Jang Y, Xi J, Wang H, Mueller RA, Norfleet EA, Xu Z. Postconditioning prevents reperfusion injury by activating delta-opioid receptors. Anesthesiology 2008; 108: 243-50.
19. Paradis P, Dumont M, Bélichard P, Rouleau JL, Lemaire S, Brakier- Gingras L. Increased preproenkephalin A gene expression in the rat heart after induction of a myocardial infarction. Biochem Cell Biol 1992; 70: 593-8.
20. Krumins SA, Faden AI, Feuerstein G. Opiate binding in rat hearts: modulation of binding after hemorrhagic shock. Biochem Biophys Res Commun 1985; 127: 120-8.
21. Schultz JE, Hsu AK, Gross GJ. Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors. Circulation 1998; 97: 1282-9.
22. Peart JN, Gross ER, Gross GJ. Effect of exogenous kappa-opioid receptor activation in rat model of myocardial infarction. J Cardiovasc Pharmacol 2004; 43: 410-5.
23. Wang GY, Wu S, Pei JM, Yu XC, Wong TM. Kappa- but not deltaopioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats. Am J Physiol Heart Circ Physiol 2001; 280: H384-91.
24. Weihrauch D, Krolikowski JG, Bienengraeber M, Kersten JR, Warltier DC, Pagel PS. Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositiol-3-kinase and opioid receptors in rabbits. Anesth Analg 2005; 101: 942-9.
25. Kuzume K, Wolff RA, Amakawa K, Kuzume K, Van Winkle DM. Sustained exogenous administration of Met5-enkephalin protects against infarction in vivo. Am J Physiol Heart Circ Physiol 2003; 285: H2463-70.
26. Schultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 1996; 78: 1100-4.
27. Fryer RM, Hsu AK, Nagase H, Gross GJ. Opioid-induced cardioprotection against myocardial infarction and arrhythmias: mitochondrial versus sarcolemmal ATP-sensitive potassium channels. J Pharmacol Exp Ther 2000; 294: 451-7.
28. Peart JN, Gross GJ. Exogenous activation of delta-and kappa-opioid receptors affords cardioprotection in isolated murine hearts. Basic Res Cardiol 2004; 99: 29-37.
29. Wong TM, Lee AY, Tai KK. Effects of drugs interacting with opioid receptors during normal perfusion or ischemia and reperfusion in the isolated rat heart-an attempt to identify cardiac opioid receptor subtype(s) involved in arrhythmogenesis. J Mol Cell Cardiol 1990; 22: 1167-75.
30. Maslov LN, Lishmanov YB, Oeltgen PR, Barzakh EI, Krylatov AV, Naryzhnaya NV, et al. Comparative analysis of the cardioprotective proterties of opioid receptor agonists in a rat model of myocardial infarction. Acad Emerg Med 2010; 17: 1239-46.
31. Förster K, Kuno A, Solenkova N, Felix SB, Krieg T. The delta-opioid receptor agonist DADLE at reperfusion protects the heart through activation of pro-survival kinases via EGF receptor transactivation. Am J Physiol Heart Circ Physiol 2007; 293: H1604-8.
32. Peart JN, Gross ER, Reichelt ME, Hsu A, Headrick JP, Gross GJ. Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts. Basic Res Cardiol 2008; 103: 454-63.
33. Kim JH, Jang YH, Chun KJ, Kim J, Park YH, Kim JS, et al. Kappaopioid receptor activation during reperfusion limits myocardial infarction via ERK1/2 activation in isolated rat hearts. Korean J Anesthesiol 2011; 60: 351-6.
34. Okubo S, Tanabe Y, Takeda K, Kitayame M, Kanemitsu S, Kukreja RC, et al. Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemia-reperfusion in rabbits: role of delta-opioid receptor. Am J Physiol Heart Crirc Physiol 2004; 287: H1786-91.
35. Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning and morphine-induced cardioprotection involve the delta-opioid receptor in the intact rat heart. J Mol Cell Cardiol 1997; 29: 2187-95.
36. Ludwig LM, Patel HH, Gross GJ, Kersten JR, Pagel PS, Warltier DC, et al. Morphine enhances pharmacological preconditioning by isoflurane: role of mitochondrial K(ATP) channels and opioid receptors. Anesthesiology 2003; 98: 705-11.
37. Cohen MV, Yang XM, Liu GS, Heusch G, Downey JM. Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial K(ATP) channels. Circ Res 2001; 89: 273-8.
38. Liang BT, Gross GJ. Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels. Circ Res 1999; 84: 1396-400.
39. McPherson BC, Yao Z. Morphine mimics preconditioning via free radical signals and mitochondrial K(ATP) channels in myocytes. Circulation 2001; 103: 290-5.
40. Miki T, Cohen MV, Downey JM. Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits. Mol Cell Biochem 1998; 186: 3-12.
41. Gross ER, Hsu AK, Gross GJ. GSK3 beta inhibition and K(ATP) channel opening mediate acute opioid-induced cardioprotection at reperfusion. Basic Res Cardiol 2007; 102: 341-9.
42. Gross ER, Hsu AK, Gross GJ. Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg 2009; 109: 1395-402.
43. Kim JH, Chun KJ, Park YH, Kim J, Kim JS, Jang YH. Morphineinduced postconditioning modulates mitochondrial permeability transition pore opening via delta-1 opioid receptors activation in isolated rat hearts. Korean J Anesthesiol 2011; 60: 351-6.
44. Chen Z, Li T, Zhang B. Morphine postconditioning protects against reperfusion injury in the isolated rat hearts. J Surg Res 2008; 145: 287-94.
45. Chang WL, Lee SS, Su MJ. Attenuation of post-ischemia reperfusion injury by thaliporphine and morphine in rat hearts. J Biomed Sci 2005; 12: 611-9.
46. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 2004; 94: 960-6.
47. Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther 2001; 89: 123-37.
48. Zhang Y, Irwin MG, Wong TM. Remifentanil preconditioning protects against ischemic injury in the intact rat heart. Anesthesiology 2004; 101: 918-23.
49. Zhang Y, Irwin MG, Wong TM, Chen M, Cao CM. Remifentanil preconditioning confers cardioprotection via cardiac kappa- and delta-opioid receptors. Anesthesiology 2005; 102: 371-8.
50. Kim HS, Cho JE, Hwang KC, Shim YH, Lee JH, Kwak YL. Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with antiapoptotic pathways of survival. Eur J Pharmacol 2010; 628: 132-9.
51. Kim HS, Kim SY, Kwak YL, Hwang KC, Shim YH. Hyperglycemia attenuates myocardial preconditioning of remifentanil. J Surg Res 2011 [in press].
52. Zhang Y, Chen ZW, Girwin M, Wong TM. Remifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats. Acta Pharmacol Sin 2005; 26: 546-50.
53. Yu CK, Li YH, Wong GT, Wong TM, Irwin MG. Remifentanil preconditioning confers delayed cardioprotection in the rat. Br J Anaesth 2007; 99: 632-8.
54. Wong GT, Li R, Jiang LL, Irwin MG. Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand 2010; 54: 510-8.
55. Kim HS, Cho JE, Hong SW, Kim SO, Shim JK, Kwak YL. Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart. Physiol Res 2010; 59: 347-56.
56. Kuzume K, Kuzume K, Wolff RA, Chien GL, Van Winkle DM. Remifentanil limits infarct size but attenuates preconditioning-induced infarct limitation. Coron Artery Dis 2004; 15: 449-55.
57. Chun KJ, Park YH, Kim JS, Jang Y, Kim JH, Kim J, et al. Comparison of 5 different remifentanil strategies against myocardial ischemiareperfusion injury. J Cardiothorac Vasc Anesth 2011 [in press].
58. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-GSK-3 beta. Am J Physiol Heart Circ Physiol 2006; 291: H827-34.
59. Peart JN, Gross GJ. Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways. Am J Physiol Heart Circ Physiol 2006; 291: H1746-53.
60. Cave AC, Hearse DJ. Ischaemic preconditioning and contractile function: studies with normothermic and hypothermic global ischaemia. J Mol Cell Cardiol 1992; 24: 1113-23.
61. Jenkins DP, Pugsley WB, Yellon DM. Ischaemic preconditioning in a model of global ischaemia: infarct size limitation, but no reduction of stunning. J Mol Cell Cardiol 1995; 27: 1623-32.
62. Couvreur N, Lucats L, Tissier R, Bize A, Berdeaux A, Ghaleh B. Differential effects of postconditioning on myocardial stunning and infarction: a study in conscious dogs and anesthetized rabbits. Am J Physiol Heart Circ Physiol 2006; 291: H1345-50.
63. Kato R, Foex P. Fentanyl reduces infarction but not stunning via delta opioid receptors and protein kinase C in rats. Br J Anaesth 2000; 84: 608-14.
64. Kloner RA, DeBoer LW, Darsee JR, Ingwall JS, Hale S, Tumas J, et al. Prolonged abnormalities of myocardium salvaged by reperfusion. Am J Physiol 1981; 241: H591-9.
65. Kato R, Ross S, Foex P. Fentanyl protects the heart against ischaemic injury via opioid receptors, adenosine A1 receptors and K(ATP) channel linked mechanisms in rats. Br J Anaesth 2000; 84: 204-14.
66. Peart JN, Gross GJ. Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. Am J Physiol Heart Circ Physiol 2003; 285: H81-9.
67. Xiao RP, Pepe S, Spurgeon HA, Capogrossi MC, Lakatta EG. Opioid peptide receptor stimulation reverses beta-adrenergic effects in rat heart cells. Am J Physiol 1997; 272: H797-805.
68. Pepe S, Xiao RP, Hohl C, Altschuld R, Lakatta EG. 'Cross talk' between opioid peptide and adrenergic receptor signaling in isolated rat heart. Circulation 1997; 95: 2122-9.
69. Pepe S, van den Brink OW, Lakatta EG, Xiao RP. Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart. Cardiovasc Res 2004; 63: 414-22.
70. Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, Ferri C, et al. Effects of naloxone on myocardial ischemic preconditioning in humans. J Am Coll Cardiol 1999; 33: 1863-9.
71. Garcia S, Henry TD, Wang YL, Chavez IJ, Pedersen WR, Lesser JR, et al. Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarction. J Cardiovasc Transl Res 2011; 4: 92-8.
72. Bell SP, Sack MN, Patel A, Opie LH, Yellon DM. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol 2000; 36: 2296-302.
73. Murphy GS, Szokol JW, Marymont JH, Avram MJ, Vender JS. Opioids and cardioprotection: the impact of morphine and fentanyl on recovery of ventricular function after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2006; 20: 493-502.
74. Pleym H, Stenseth R, Wiseth R, Karevold A, Dale O. Supplemental remifentanil during coronary artery bypass grafting is followed by a transient postoperative cardiac depression. Acta Anaesthesiol Scand 2004; 48: 1155-62.
75. Xu ZD, Jin M, He WX, Xia SX, Zhao YF, He B, et al. Remifentanil preconditioning lowers cardiac troponin 1 level in patients undergoing off-pump coronary artery bypass graft surgery. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29: 1554-6 [Article in Chinese].
76. Wong GT, Huang Z, Ji S, Irwin MG. Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial. J Cardiothorac Vasc Anesth 2010; 24: 790-6.